What are the recent financial highlights of JUBILANT PHARMOVA LTD?

JUBILANT PHARMOVA LTD recently reported a total revenue of ₹7,064.30 Cr and a net profit margin of 8.88%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of JUBILANT PHARMOVA LTD?

JUBILANT PHARMOVA LTD offers a dividend yield of 0.54%, with a dividend rate of ₹5.0 per share.

What are the key financial metrics of JUBILANT PHARMOVA LTD?

Key financial metrics include a trailing P/E ratio of 22.000505, forward P/E of 25.704142, book value of ₹373.882, price-to-book ratio of 2.3237278, and a market capitalization of ₹137.62 billion.

What does JUBILANT PHARMOVA LTD do?

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Jublpharma

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Jublpharma

Latest updates related to Jublpharma

Sr No.	Title	Sentiment
1	Do Jubilant Pharmova's (NSE:JUBLPHARMA) Earnings Warrant Your Attention? Simply Wall St	🔄
2	Jubilant Pharmova (NSE:JUBLPHARMA) advances 8.1% this week, taking one-year gains to 157% Simply Wall St	🔄
3	Insufficient Growth At Jubilant Pharmova Limited (NSE:JUBLPHARMA) Hampers Share Price Simply Wall St	🔄
4	JUBLPHARMA Stock Price and Chart — NSE:JUBLPHARMA TradingView	🔄
5	Is The Market Rewarding Jubilant Pharmova Limited (NSE:JUBLPHARMA) With A Negative Sentiment As A Result Of Its Mixed Fundamentals? Simply Wall St	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Jublpharma

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks